Declining childhood and adolescent cancer mortality

Cancer

Volumn 120, Issue 16, 2014, Pages 2497-2506

  Smith, Malcolm A ^a   Altekruse, Sean F ^a   Adamson, Peter C ^b   Reaman, Gregory H ^c   Seibel, Nita L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

adolescents; childhood cancer; childhood leukemia; childhood solid tumors; mortality rates

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER SURVIVAL; CANCER SURVIVOR; CANCER THERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; GONAD TUMOR; HODGKIN DISEASE; HUMAN; MORTALITY; NEUROBLASTOMA; NEWBORN; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; QUALITY OF LIFE; SOLID TUMOR; TREND STUDY; UNITED STATES; CANCER REGISTRY; EPIDEMIOLOGY; INCIDENCE; NEOPLASMS; SURVIVOR; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; HUMANS; INCIDENCE; MORTALITY; NEOPLASMS; SEER PROGRAM; SURVIVORS; UNITED STATES; YOUNG ADULT;

EID: 84905565527     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28748     Document Type: Article

References (33)

1. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: challenges for the 21st century. J Clin Oncol. 2010; 28: 2625-2634.
2. Pritchard-Jones K, Pieters R, Reaman GH, et al. Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries [serial online]. Lancet Oncol. 2013; 14: e95-e103.
3. National Cancer Institute; Surveillance, Epidemiology, and End Results (SEER) Population Estimates Used in NCI's SEER*Stat Software. Available at: http://seer.cancer.gov/popdata/methods.html. Accessed September 1, 2012.
4. Kim HJ, Fay MP, Feuer EJ, Midthune DN,. Permutation tests for joinpoint regression with applications to cancer rates. Stat Med. 2000; 19: 335-351.
5. Stiller CA, Kroll ME, Pritchard-Jones K,. Population survival from childhood cancer in Britain during 1978-2005 by eras of entry to clinical trials. Ann Oncol. 2012; 23: 2464-2469.
6. Bostrom BC, Sensel MR, Sather HN, et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood. 2003; 101: 3809-3817.
7. Matloub Y, Bostrom BC, Hunger SP, et al. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2011; 118: 243-251.
8. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008; 111: 2548-2555.
9. Larsen EC, Salzer WL, Devidas M, et al. Comparison of high-dose methotrexate (HD-MTX) with Capizzi methotrexate plus asparaginase (C-MTX/ASNase) in children and young adults with high-risk acute lymphoblastic leukemia (HR-ALL): a report from the Children's Oncology Group Study AALL0232 [abstract]. J Clin Oncol. 2011; 29S. Abstract 3.
10. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol. 2009; 27: 5175-5181.
11. Schultz KR, Bowman WP, Slayton W, et al. Improved early event free survival (EFS) in children with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with intensive imatinib in combination with high dose chemotherapy: Children's Oncology Group (COG) Study AALL0031 [abstract]. Blood (ASH Annual Meeting Abstracts). 2007; 110. Abstract 4.
12. Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012; 30: 4148-4154.
13. Ferrari A, Montello M, Budd T, Bleyer A,. The challenges of clinical trials for adolescents and young adults with cancer. Pediatr Blood Cancer. 2008; 50 (5 suppl): 1101-1104.
14. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008; 112: 1646-1654.
15. Nachman JB, La MK, Hunger SP, et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the Children's Oncology Group. J Clin Oncol. 2009; 27: 5189-5194.
16. Kantarjian H, Thomas D, Wayne AS, O'Brien S,. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol. 2012; 30: 3876-3883.
17. Iland HJ, Bradstock K, Supple SG, et al; Australasian Leukaemia and Lymphoma Group. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012; 120: 1570-1580.
18. Powell BL, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood. 2010; 116: 3751-3757.
19. Mosse YP, Balis FM, Lim MS, et al. Efficacy of crizotinib in children with relapsed/refractory ALK-driven tumors including anaplastic large cell lymphoma and neuroblastoma: a Children's Oncology Group phase I consortium study [abstract]. J Clin Oncol. 2012; 30S. Abstract 9500.
20. Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in Patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012; 30: 2190-2196.
21. Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010; 363: 1324-1334.
22. Capitini CM, Gottschalk S, Brenner M, Cooper LJ, Handgretinger R, Mackall CL,. Highlights of the second international conference on "Immunotherapy in Pediatric Oncology." Pediatr Hematol Oncol. 2011; 28: 459-460.
23. Orentas RJ, Lee DW, Mackall C,. Immunotherapy targets in pediatric cancer [serial online]. Front Oncol. 2012; 2: 3.
24. Lee DW, Barrett DM, Mackall C, Orentas R, Grupp SA,. The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res. 2012; 18: 2780-2790.
25. Dougherty MJ, Santi M, Brose MS, et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol. 2010; 12: 621-630.
26. Pfister S, Janzarik WG, Remke M, et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest. 2008; 118: 1739-1749.
27. Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011; 121: 397-405.
28. Khuong-Quang DA, Buczkowicz P, Rakopoulos P, et al. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol. 2012; 124: 439-447.
29. Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature. 2012; 482: 226-231.
30. Wu G, Broniscer A, McEachron TA, et al. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet. 2012; 44: 251-253.
31. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008; 455: 1061-1068.
32. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321: 1807-1812.
33. Connor E, Cure P,. "Creating hope" and other incentives for drug development for children [serial online]. Sci Transl Med. 2011; 3: 66cm1.